Source-grounded facts extracted from AtriCure, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
AtriCure, Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers as disclosed in the proxy statement.
“5. The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement. For: 40,373,427 Against: 1,745,379 Abstain: 62,342 Broker Non-Votes: 3,820,943”
AtriCure, Inc. shareholders approved Approve amendment to AtriCure, Inc. 2018 Employee Stock Purchase Plan to increase number of shares by 750,000.
“4. The stockholders approved the amendment to the AtriCure, Inc. 2018 Employee Stock Purchase Plan to increase the number of shares of common stock authorized by 750,000. For: 42,064,798 Against: 109,893 Abstain: 6,457 Broker Non-Votes: 3,820,943”
AtriCure, Inc. shareholders approved Approve amendment to AtriCure, Inc. 2023 Stock Incentive Plan to increase number of shares by 1,500,000.
“3. The stockholders approved the amendment to the AtriCure, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 1,500,000 . For: 41,051,336 Against: 1,066,332 Abstain: 63,480 Broker Non-Votes: 3,820,943”
AtriCure, Inc. shareholders approved Ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-12-31 meeting.
“2. The stockholders approved the proposal to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. For: 43,617,566 Against: 2,327,505 Abstain: 57,020”
AtriCure, Inc. shareholders approved Election of nine directors to serve one-year terms expiring at the 2027 Annual Meeting of Stockholders.
“Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,848,141 264,297 68,710 3,820,943 Regina E. Groves 41,852,934 258,662 69,552 3,820,943 B. Kristine Johnson 41,685,893 426,149 69,106 3,820,943 Shlomo Nachman 41,846,048 260,889 74,211 3,820,943 Karen N. Prange 41,514,921 590,763 75,464 3,820,943 Deborah H. Telman 40,917,973 1,192,573 70,602 3,820,943 Sven A. Wehrwein 41,454,342 653,542 73,264 3,820,943 Robert S. White 41,025,795 1,086,032 69,321 3,820,943 Maggie Yuen 41,447,687 663,914 69,547 3,820,943”
AtriCure, Inc. reported the first quarter ended March 31, 2026 results: revenue $141.2 million, net income $0.1 million, EPS $0.00.
“First Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year • First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million”
AtriCure, Inc. reported first quarter ended March 31, 2026 results: revenue $141.2 million, net income $0.1 million, EPS breakeven at $0.00.
“or document. --- EX-99.1 (EX-99.1) --- For immediate release May 5, 2026 AtriCure Reports First Quarter 2026 Financial Results • First Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year • First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million • U.S. revenue growth”
AtriCure, Inc. amended First Amendment to Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, bookrunner and lead arranger, and the lenders party thereto (effective 2026-01-09).
“On January 9, 2026 (the “ Closing Date ”), AtriCure, Inc. (the “ Company ”) and its wholly owned subsidiary, AtriCure, LLC (together with the Company, the “ Borrowers ”), entered into a First Amendment (“ First Amendment ”) to Credit Agreement (as amended, the “ Credit Agreement ”) among the Borrowers, JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “ Administrative Agent ”), JPMorgan Chase Bank, N.A., as bookrunner and lead arranger (“ JPMCB ”), and the lenders party thereto (“ Lenders ”).”
AtriCure, Inc.: Amendment to Second Amended and Restated Certificate of Incorporation to limit liability of certain officers (effective 2024-05-13).
“At the Annual Meeting, the stockholders of the Company approved an amendment (the “Amendment”) to the Company’s Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by the Delaware General Corporation Law. The Amendment became effective immediately upon the filing of a certificate of amendment setting forth the same with the Secretary of State of the State of Delaware on May 13, 2024.”
AtriCure, Inc. shareholders approved Approval of an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company at the 2024-05-14 meeting.
“5. The stockholders approved the amendment to the Company’s Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company. For: 37,737,714 Against: 4,398,481 Abstain: 78,142 Broker Non-Votes: 2,575,972”
AtriCure, Inc. shareholders approved Approval of an amendment to the AtriCure, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 1,800,000 at the 2024-05-14 meeting.
“4. The stockholders approved the amendment to the AtriCure, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 1,800,000. For: 40,884,921 Against: 1,252,515 Abstain: 76,901 Broker Non-Votes: 2,575,972”
AtriCure, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers as disclosed in the proxy statement at the 2024-05-14 meeting.
“3. The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement. For: 35,640,238 Against: 6,475,860 Abstain: 98,239 Broker Non-Votes: 2,575,972”
AtriCure, Inc. shareholders approved Ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-14 meeting.
“2. The stockholders approved the proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. For: 44,157,266 Against: 550,817 Abstain: 82,226”
AtriCure, Inc. shareholders approved Election of Maggie Yuen as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of Robert S. White as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of Sven A. Wehrwein as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of Deborah H. Telman as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of Karen N. Prange as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of Shlomo Nachman as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of B. Kristine Johnson as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of Regina E. Groves as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of Michael H. Carrel as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. reported financial results for the fourth quarter and full-year ended December 31, 2023.
“On February 15, 2024 , AtriCure, Inc. issued a press release regarding its financial results for the fourth quarter and full-year ended December 31, 2023.”
AtriCure, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $106.5 million, EPS adjusted loss per share of approximately $0.74 to $0.76. Guidance initiated.
“financial results for the fourth quarter and full year 2023 and provided 2024 financial guidance. Preliminary, unaudited revenue for fourth quarter 2023 is expected to be $106.5 million, reflecting growth of approximately 21% over the fourth quarter of 2022 (20% on a constant currency basis). U.S. revenue is expected to be $88.7 million, reflecting growth of”
AtriCure, Inc. incurred credit facility of up to $125 million (with potential increase up to $165 million) with JPMorgan Chase Bank, N.A., Silicon Valley Bank, a Division of First-Citizen Bank & Trust Company at ABR plus applicable margin or adjusted term SOFR rate plus applicable margin maturing three-year.
“On January 5, 2024 (the “ Closing Date ”), AtriCure, Inc. (the “ Company ”) and its wholly owned subsidiary, AtriCure, LLC (together with the Company, the “ Borrowers ”), entered into an asset-based credit agreement (the “ Credit Agreement ”) among the Borrowers, JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “ Administrative Agent ”), JPMorgan Chase Bank, N.A. (“JPMCB”) and Silicon Valley Bank, a Division of First-Citizen Bank & Trust Company (“SVB”), as Joint Lead Arrangers and Joint Bookrunners, and the lenders party thereto (“Lenders”). The Credit Agreement provides for an asset-based three-year revolving credit facility (the “ ABL Facility ”) in an amount of up to $125 million.”
AtriCure, Inc. terminated Loan and Security Agreement dated as of February 23, 2018, by and among SVB, the Company and certain subsidiaries (as amended, the “ SVB Facility ”) with SVB (effective 2024-01-05).
“Proceeds also were used to refinance the Company’s indebtedness under the Loan and Security Agreement dated as of February 23, 2018, by and among SVB, the Company and certain subsidiaries (as amended, the “ SVB Facility ”). The SVB Facility terminated on the Closing Date.”
AtriCure, Inc. entered into Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, JPMorgan Chase Bank, N.A. and Silicon Valley Bank, a Division of First-Citizen Bank & Trust Company, as Joint Lead Arrangers and Joint Bookrunners, and the lenders party thereto valued at $125 million (effective 2024-01-05).
“On January 5, 2024 (the “ Closing Date ”), AtriCure, Inc. (the “ Company ”) and its wholly owned subsidiary, AtriCure, LLC (together with the Company, the “ Borrowers ”), entered into an asset-based credit agreement (the “ Credit Agreement ”) among the Borrowers, JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “ Administrative Agent ”), JPMorgan Chase Bank, N.A. (“JPMCB”) and Silicon Valley Bank, a Division of First-Citizen Bank & Trust Company (“SVB”), as Joint Lead Arrangers and Joint Bookrunners, and the lenders party thereto (“Lenders”).”
Shlomi Nachman was elected as director at AtriCure, Inc..
“elected Shlomi Nachman to serve as a director until the next Annual Meeting of Stockholders.”
AtriCure, Inc. reported third quarter ended September 30, 2023 results: revenue $98.3 million, net income Net loss of $9.1 million, EPS $0.20.
“Worldwide revenue of $98.3 million – an increase of 18.1% year over year • U.S. revenue of $81.7 million – an increase of 17.1% year over year • International revenue of $16.6 million – an increase of 23.2% year over year • Net loss of $9.1 million – an improvement of $3.2 million year over year”
AtriCure, Inc. reported the second quarter ended June 30, 2023 results: revenue $100.9 million, net income Net loss of $5.1 million, EPS $0.11. Guidance reaffirmed.
“in any such filing or document. --- EX-99.1 (EX-99.1) --- For immediate release July 25, 2023 AtriCure Reports Second Quarter 2023 Financial Results • Worldwide revenue of $100.9 million – an increase of 19.4% year over year • U.S. revenue of $84.9 million – an increase of 19.1% year over year • International revenue of $16.0 million – an increase of 20.7% year”
AtriCure, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers as disclosed in the proxy statement at the 2023-05-25 meeting.
“The advisory vote on the compensation of the Company’s named executive officers as disclosed in the proxy statement received the following votes: For: 33,710,016 Against: 6,620,611 Abstain: 63,645 Broker Non-Votes: 2,455,488”
AtriCure, Inc. shareholders approved Approval of an amendment to the AtriCure, Inc. 2018 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 750,000 at the 2023-05-25 meeting.
“The approval of an amendment to the AtriCure, Inc. 2018 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 750,000 received the following votes: For: 40,320,811 Against: 48,473 Abstain: 24,988 Broker Non-Votes: 2,455,488”
AtriCure, Inc. shareholders approved Approval of the AtriCure, Inc. 2023 Stock Incentive Plan at the 2023-05-25 meeting.
“The approval of the AtriCure, Inc. 2023 Stock Incentive Plan received the following votes: For: 38,096,753 Against: 2,269,227 Abstain: 28,292 Broker Non-Votes: 2,455,488”
AtriCure, Inc. shareholders approved Ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-25 meeting.
“The proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 received the following votes: For: 42,108,324 Against: 711,131 Abstain: 30,305 Broker Non-Votes: 0”
AtriCure, Inc. shareholders approved Election of eight directors to serve one-year terms expiring at the 2024 Annual Meeting of Stockholders at the 2023-05-25 meeting.
“The stockholders of the Company voted on five items at the Annual Meeting of Stockholders held on May 25, 2023: 1. The election of eight directors to serve one-year terms expiring at the 2024 Annual Meeting of Stockholders and until their successors have been duly elected and qualified; 2. A proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023; 3. The approval of the AtriCure, Inc. 2023 Stock Incentive Plan; 4. The approval of an amendment to the AtriCure, Inc. 2018 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 750,000; and 5. An advisory vote on the compensation of the Company’s named executive officers as disclosed in the proxy statement.”
AtriCure, Inc. reported Full Year 2023 results: revenue $380 million to $387 million, EPS $1.14 to $1.19. Guidance initiated.
“Full year 2023 revenue is projected to be approximately $380 million to $387 million, reflecting growth of approximately 15% to 17% over full year 2022. Full year 2023 adjusted EBITDA is expected to break even, with improvements annually thereafter. Full year 2023 adjusted loss per share is expected to be in the range of $1.14 to $1.19.”
AtriCure, Inc. reported Full Year 2022 results: revenue $330.4 million, EPS -$1.02.
“Revenue for 2022 was $330.4 million, an increase of $56.1 million or 20.4% (an increase of 21.8% on a constant currency basis), compared to 2021 revenue. U.S. revenue increased 21.0% to $277.2 million. International revenue was $53.2 million, an increase of $8.0 million or 17.7% (an increase of 25.7% on a constant currency basis). Gross profit for 2022 was $245.9 million compared to $205.9 million for 2021, and gross margin decreased to 74.4% for 2022 compared to 75.0% for 2021. Loss from operations for 2022 was $42.7 million, compared to income from operations of $55.2 million for 2021. Income from operations in 2021 includes a $184.8 million credit to operating expenses for the change in fair value of contingent consideration, offset partially by a $82.3 million intangible asset impairment charge for the IPR&D asset associated with the aMAZETM trial. Basic and diluted net loss per share was $1.02 for 2022, compared to basic and diluted income per share of $1.11 and $1.09, respectivel”
AtriCure, Inc. reported Fourth Quarter 2022 results: revenue $88.0 million, EPS -$0.09.
“Revenue for the fourth quarter 2022 was $88.0 million, an increase of 20.2% (an increase of 21.5% on a constant currency basis) over fourth quarter 2021 revenue. U.S. revenue was $73.9 million, an increase of $12.7 million or 20.7%, compared to fourth quarter 2021 revenue. U.S. revenue reflected strong growth across our open ablation, pain management and appendage management product lines, driven by sales of our EnCompass ® clamp, cryoSPHERE ® and AtriClip ® Flex⋅V ® products. International revenue increased $2.1 million or 17.8% (an increase of 25.4% on a constant currency basis) to $14.1 million, reflecting growth in appendage management and open ablation franchises. On a sequential basis, worldwide revenue for the fourth quarter 2022 increased approximately 5.7% over third quarter 2022. Gross profit for the fourth quarter 2022 was $65.1 million compared to $55.0 million for the fourth quarter 2021. Gross margin was 74.0% and 75.1% for the fourth quarters 2022 and 2021, reflecting ch”
AtriCure, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $330.4 million, EPS approximately $1.10 to $1.12. Guidance initiated.
“Preliminary, unaudited revenue for fourth quarter 2022 is expected to be approximately $88.0 million, reflecting growth of approximately 20% over the fourth quarter of 2021 (21% on a constant currency basis).”
AtriCure, Inc. reported the third quarter ended September 30, 2022 results: revenue $83.2 million, EPS $0.27.
“Revenue for the third quarter 2022 was $83.2 million, an increase of 18.1% (an increase of 19.8% on a constant currency basis) over third quarter 2021 revenue.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.